Artículo Original 97 CONSENSO CHILENO DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE - C. Hernández-Rocha et al. strain GG. Clin Infect Dis 1999; 28: 1159-60. 54.- Sipsas NV, Zonios DI, Kordossis T. Safety of Lactobacillus strains used as probiotic agents. Clin Infect Dis 2002; 34: 1283-4; author reply 1284-5. 55.- Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-34. 56.- Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38: 62-9. 57.- Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115: 178-81. 58.- Riquelme AJ, Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36: 41-3. 59.- de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Engin/Biotechnol 2008; 111: 1-66. 60.- Lewis S, Burmeister S, Cohen S, Brazier J, Awasthi A. Failure of dietary oligofructose to prevent antibioticassociated diarrhoea. Alimentary Pharmacol Ther 2005; 21: 469-77. 61.- Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3: 442-8. 62.- Speight S, Moy A, Macken S, Chitnis R, Hoffman PN, Davies A, et al. Evaluation of the sporicidal activity of different chemical disinfectants used in hospitals against Clostridium difficile. J Hosp Infect 2011; 79: 18-22. 63.- Faires MC, Pearl DL, Ciccotelli WA, Straus K, Zinken G, Berke O, et al. A prospective study to examine the epidemiology of methicillin-resistant Staphylococcus aureus and Clostridium difficile contamination in the general environment of three community hospitals in southern Ontario, Canada. BMC Infect Dis 2012; 12: 290. 64.- Eckstein BC, Adams DA, Eckstein EC, Rao A, Sethi AK, Yadavalli GK, et al. Reduction of Clostridium difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods. BMC Infect Dis 2007; 7: 61. 65.- Kirkland KB, Homa KA, Lasky RA, Ptak JA, Taylor EA, Splaine ME. Impact of a hospital-wide hand hygiene initiative on healthcare-associated infections: results of an interrupted time series. BMJ Qual Safety 2012; 21: 1019-26. 66.- Suzuki H, Senda J, Yamashita K, Tokuda Y, Kanesaka Y, Kotaki N, et al. Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. J Infect Chemother 2013; 19: 1047-52. 67.- Backman C, Taylor G, Sales A, Marck P B. An integrative review of infection prevention and control programs for multidrug-resistant organisms in acute care hospitals: a socio-ecological perspective. Am J Infect Control 2011; 39: 368-78. 68.- Salgado CD, Mauldin PD, Fogle PJ, Bosso JA. Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. Am J Infect Control 2009; 37: 458-64. 69.- Price J, Cheek E, Lippett S, Cubbon M, Gerding DN, Sambol SP, et al. Impact of an intervention to control Clostridium difficile infection on hospital and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect 2010; 16: 1297-302. 70.- Muto CA, Blank MK, Marsh JW, Vergis EN, O’Leary MM, Shutt KA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007; 45: 1266-73. 71.- Dubberke ER, Gerding DN, Classen D, Arias KM, Podgorny K, Anderson DJ, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1: S81-92. 72.- Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tull P, Gastmeier P, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 Suppl 5: 2-20. 73.- Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo V G, Mcdonald LC, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35 Suppl 2: S48-65. 74.- Doan L, Forrest H, Fakis A, Craig J, Claxton L, Khare M. Clinical and cost effectiveness of eight disinfection methods for terminal disinfection of hospital isolation rooms contaminated with Clostridium difficile 027. J Hosp Infect 2012; 82: 114-21. 75.- Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, et al. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Applied Environ Microbiol 2010; 76: 6895-900. 76.- Macleod-Glover N, Sadowski C. Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-associated diarrhea in geriatric rehabilitation. Can Fam Phys Med Fam Can 2010; 56: 417-23. 77.- Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile. Lancet 2000; 356: 1324. 78.- Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR. Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Control 2010; 38: 350-3. 79.- Barbut F, Menuet D, Verachten M, Girou E. Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores. Infect Control Hosp Epidemiol 2009; 30: 507-14. 80.- Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Gastroenterol. latinoam 2016; Vol 27, Nº 2: 79-100
gastro 2 2016
To see the actual publication please follow the link above